ALS
Stories
-
Specific Biologics announces oversubscribed US$35 million Series A financing
Specific Biologics announced the closing of an oversubscribed US$35 million Series A financing led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations and other investors. The proceeds will be used to advance the lead Dualase therapeutic candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II clinical trial in patients with C9ORF72-associated ALS.